Journal

GLP-1s and PCOS: Promising Signals, Thin Evidence, and a Fertility Warning

Trials are examining whether semaglutide restores ovulation. That raises a contraception question most providers do not mention.

Why PCOS is a plausible target

Polycystic ovary syndrome commonly involves insulin resistance, and weight reduction is an established part of management. GLP-1 receptor agonists act on both, which makes them a reasonable candidate — and metformin, which also targets insulin resistance, has long been used off-label in PCOS.

The RESTORE programme is examining semaglutide's role in restoring ovulation in youth and adults with PCOS. That endpoint — ovulation rather than weight — is the interesting part, because it tests whether the benefit runs beyond the scale.

What the evidence supports today

Less than the marketing in this space implies. There is a mechanistic rationale, there is evidence that weight reduction improves PCOS parameters, and there are trials underway. What does not yet exist is a large body of completed randomised evidence showing GLP-1s outperform existing management on PCOS-specific outcomes.

No GLP-1 is approved for PCOS. Prescribing for it is off-label, which is lawful and common but should be disclosed to you as such.

The fertility point nobody puts on a landing page

If treatment restores ovulation in someone who has not been ovulating, fertility may return — potentially before they expect it and possibly without the usual signals they would recognise.

GLP-1 receptor agonists are not recommended during pregnancy, and the Zepbound label notes potential fetal harm. So a treatment that could restore fertility, in a drug that should not be continued in pregnancy, creates a contraception conversation that ought to happen before the first dose rather than after.

This is the single most practically important thing on this page, and it is routinely absent from PCOS-adjacent GLP-1 marketing.

What to discuss with a clinician

1. Is this being prescribed off-label for PCOS, and what does the evidence actually support?
2. If I am not currently ovulating, what happens if treatment changes that?
3. What contraception plan applies while I am on this?
4. What is the plan if I want to conceive — how long before, and what do I switch to?
5. How does this compare with metformin or other options for my specific presentation?

What the evidence does not establish

Whether GLP-1s improve live birth rates. Whether benefit persists after stopping. Whether they outperform existing management. And nothing at all about compounded preparations, microdoses or oral formulations in a PCOS population — no trial has studied any of those.

How this compares with existing management

Metformin has been used off-label in PCOS for decades on the same insulin-resistance rationale, and lifestyle intervention with weight reduction is established first-line management where weight is a factor. Combined hormonal contraception addresses cycle regulation and androgenic symptoms.

A GLP-1 is not obviously better than any of these on current evidence — it is a newer option with a stronger weight-reduction effect and a thinner PCOS-specific evidence base. Which matters more depends on the presentation.

Why the ovulation endpoint is the interesting one

Weight reduction improving PCOS parameters is established and unsurprising. A trial measuring ovulation directly tests something else: whether the intervention restores the function that defines much of the syndrome's impact.

If it does, the implications run beyond weight — for cycle regularity, for endometrial protection, and for fertility. That last one is why this article carries a warning rather than only a summary.

The contraception conversation, in more detail

Someone with PCOS who has not been ovulating may not use contraception, may not track cycles, and may not recognise the return of fertility. A treatment that restores ovulation can therefore produce an unplanned pregnancy in someone who believed conception was unlikely.

GLP-1 receptor agonists are not recommended in pregnancy, and the tirzepatide label notes potential fetal harm. So the sequence matters: contraception discussion before the first dose, not after a positive test.

If you are taking a GLP-1 and planning to conceive, the discussion is about how far in advance to stop, what to switch to, and what happens to weight and PCOS parameters in the interval — none of which has a standard answer.

What compounded products change here

Nothing favourable. No compounded preparation has been studied in PCOS, in fertility, or in any population. Off-label prescribing of an approved product at least means the product itself has been reviewed.

Why the evidence is thinner than the marketing

PCOS affects a large population, is under-served by existing treatment, and correlates with insulin resistance. That combination makes it commercially attractive to market toward, well ahead of the trial evidence.

Off-label prescribing is lawful and often appropriate. What is not appropriate is presenting an off-label use as though it carried the same evidentiary weight as an approved indication, and that distinction is frequently blurred in this space.

What to ask about monitoring

1. What PCOS-specific markers will you track, and how often?
2. How will we know whether this is working beyond the scale?
3. What would make you stop or switch?

Questions readers actually ask